Program
sacituzumab tirumotecan
Also written as “Sacituzumab tirumotecan”, “SKB264” and “Sacituzumab Tirumotecan”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms · Ovarian Neoplasms · Endometrial Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 2928 open or running | phase 3since Oct 3, 2023 | Apr 1, 2022 | May 10, 2027phase 3 · NCT06074588 |
| Sichuan Kelun Pharmaceutical | 1716 open or running | phase 3since Apr 15, 2022 | Apr 15, 2022 | Nov 2026phase 3 · NCT06448312 |
| Klus Pharma | 33 open or running | phase 2since Oct 29, 2019 | Oct 29, 2019 | Nov 30, 2027phase 2 · NCT05642780 |
| Convalife (Shanghai) | 11 open or running | phase 2since Aug 22, 2025 | Aug 22, 2025 | Aug 12, 2028phase 2 · NCT07157956 |
- Named in Merck’s own pipeline as
sacituzumab tirumotecan (MK-2870)
, phase 4, as of Nov 2, 2026 (source).
Also a collaborator on its studies: Daiichi Sankyo and Myriad Genetics.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseMerck licensed it from Kelun-Biotech, for everywhere outside Greater China.Source: Merck, Nov 4, 2025
How Klus Pharma and Convalife (Shanghai) relate to it is not in the registry or these sources.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since Oct 29, 2019.
- May 4, 2025Phase 3 study in Breast NeoplasmsMerck · NCT06966700 · 2,400 planned · United States, Argentina, Australia and more
- Jun 19, 2025Phase 3 study in Breast NeoplasmsSichuan Kelun Pharmaceutical · NCT07071337 · 430 planned · China
- Aug 22, 2025Convalife (Shanghai)’s first study: phase 2 study in Advanced Solid TumorNew to Convalife (Shanghai)Convalife (Shanghai) · NCT07157956 · 318 planned · China
- Oct 10, 2025Phase 3 study in Uterine Cervical NeoplasmsMerck · NCT07216703 · 1,023 planned · United States, Argentina, Austria and more
- Nov 20, 2025Phase 2 study in NeoplasmsMerck · NCT07252739 · 140 planned · United States, Chile, China and more
- Dec 11, 20253 phase 2 studiesSichuan Kelun Pharmaceutical · NCT07329322, NCT07324629, NCT07341100
- Jan 2, 2026Phase 3 study in Ovarian NeoplasmsMerck · NCT07318558 · 900 planned · United States, Argentina, Australia and more
- Feb 10, 2026Phase 3 study in Urinary Bladder NeoplasmsMerck · NCT07419295 · 590 planned · United States, Argentina, Australia and more
- May 7, 2026Phase 2 study in Advanced Solid TumorsSichuan Kelun Pharmaceutical · NCT07586943 · 530 planned · China
- Jul 3, 2026Phase 2 study in NSCLCSichuan Kelun Pharmaceutical · NCT07697586 · 206 planned · China
- Sep 15, 2026Phase 3 study in Urinary Bladder NeoplasmsMerck · NCT07829783 · 400 planned · Taiwan, Ukraine
- Sep 28, 2026Phase 2 study in Non-Squamous Non-Small Cell Lung CancerSichuan Kelun Pharmaceutical · NCT07854509 · 110 planned
- Oct 21, 2026Primary completion moved from 2026-07 to 2027-04Date moved laterphase 3 · +9 months · NCT06279364
- Oct 26, 2026Phase 2 study in Metastatic Castration-resistant Prostate CancerMerck · NCT07908524 · 290 planned
Ahead
- Nov 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungSichuan Kelun Pharmaceutical · NCT06448312
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungSichuan Kelun Pharmaceutical · NCT06711900
- Dec 30, 2026Primary completion: phase 2 study in Selected Subjects With Advanced Solid TumorsSichuan Kelun Pharmaceutical · NCT05631262
- Dec 31, 2026Primary completion: phase 3 study in Breast NeoplasmsSichuan Kelun Pharmaceutical · NCT06081959
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugate…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
All 50 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07908524Metastatic Castration-resistant Prostate Cancer | 2 | Not yet recruiting | Merck | Jun 29, 2032 | 290 |
| NCT07854509Non-Squamous Non-Small Cell Lung Cancer | 2 | Not yet recruiting | Sichuan Kelun Pharmaceutical | Dec 30, 2027 | 110 |
| NCT07829783Urinary Bladder Neoplasms · Taiwan, Ukraine | 3 | Recruiting | Merck | Nov 17, 2031 | 400 |
| NCT07697586NSCLC · China | 2 | Recruiting | Sichuan Kelun Pharmaceutical | Aug 2028 | 206 |
| NCT07586943Advanced Solid Tumors · China | 2 | Recruiting | Sichuan Kelun Pharmaceutical | Dec 2029 | 530 |
| NCT07419295Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Jul 27, 2029 | 590 |
| NCT07318558Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Feb 25, 2033 | 900 |
| NCT07341100Carcinoma, Ovarian Epithelial · China | 2 | Active, not recruiting | Sichuan Kelun Pharmaceutical | Jan 2028 | 20 |
| NCT07329322Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Sichuan Kelun Pharmaceutical | Aug 31, 2027 | 30 |
| NCT07324629Thymoma · China | 2 | Recruiting | Sichuan Kelun Pharmaceutical | Apr 2028 | 30 |
| NCT07252739Neoplasms · United States, Chile, China and more | 2 | Recruiting | Merck | Nov 15, 2029 | 140 |
| NCT07216703Uterine Cervical Neoplasms · United States, Argentina, Austria and more | 3 | Recruiting | Merck | Oct 29, 2031 | 1,023 |
| NCT07157956Advanced Solid Tumor · China | 2 | Not yet recruiting | Convalife (Shanghai) | Aug 12, 2028 | 318 |
| NCT07071337Breast Neoplasms · China | 3 | Recruiting | Sichuan Kelun Pharmaceutical | Jul 2027 | 430 |
| NCT06966700Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Mar 23, 2033 | 2,400 |
| NCT06952504Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | May 24, 2032 | 1,123 |
| NCT06841354Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | May 18, 2030 | 1,000 |
| NCT06824467Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Apr 27, 2029 | 770 |
| NCT06788912Lung Neoplasms · United States, Chile, Greece and more | 2 | Active, not recruiting | Merck | Feb 6, 2032 | 60 |
| NCT06780111Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more | 2 | Recruiting | Merck | Jan 4, 2032 | 298 |
| NCT06711900Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Sichuan Kelun Pharmaceutical | Dec 2026 | 432 |
| NCT06670196Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Sichuan Kelun Pharmaceutical | May 2027 | 420 |
| NCT06637423Non-Muscle Invasive Bladder Neoplasms · United States, Canada, France and more | 2 | Completed | Merck | Sep 30, 2026 | 35 |
| NCT06483334Carcinoma, Transitional Cell · United States, Canada, France and more | 2 | Active, not recruiting | Merck | Mar 31, 2028 | 38 |
| NCT06469944Esophageal Neoplasms · United States, Brazil, Chile and more | 2 | Recruiting | Merck | Sep 12, 2029 | 160 |
| NCT06459180Uterine Cervical Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Jun 15, 2028 | 686 |
| NCT06448312Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Sichuan Kelun Pharmaceutical | Nov 2026 | 406 |
| NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more | 2 | Recruiting | Merck | May 9, 2028 | 210 |
| NCT06428409Colorectal Neoplasms · United States, Australia, Canada and more | 2 | Recruiting | Merck | Oct 16, 2029 | 220 |
| NCT06422143Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Recruiting | Merck | Jan 12, 2029 | 851 |
| NCT06393374Triple Negative Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Dec 16, 2030 | 1,530 |
| NCT06356311Adenocarcinoma Of Esophagus · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Merck | Oct 19, 2026 | 473 |
| NCT06312137Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Feb 21, 2034 | 780 |
| NCT06312176Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Jul 11, 2027 | 1,200 |
| NCT06305754Carcinoma, Non-Small-Cell Lung · United States, Argentina, Canada and more | 3 | Active, not recruiting | Merck | Aug 17, 2028 | 550 |
| NCT06279364Triple Negative Breast Neoplasms · China | 3 | Active, not recruiting | Sichuan Kelun Pharmaceutical | Apr 2027 | 537 |
| NCT06170788Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Jan 25, 2028 | 614 |
| NCT06132958Endometrial Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Merck | Jan 10, 2028 | 710 |
| NCT06081959Breast Neoplasms · China | 3 | Recruiting | Sichuan Kelun Pharmaceutical | Dec 31, 2026 | 376 |
| NCT06074588Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | Merck | May 10, 2027 | 556 |
| NCT06049212Carcinoma, Non-Small-Cell Lung · Japan | 1 | Active, not recruiting | Merck | Dec 31, 2027 | 30 |
| NCT05870319Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Sichuan Kelun Pharmaceutical | Jul 11, 2024 | 376 |
| NCT05816252Carcinoma, Non-Small-Cell Lung · China, Georgia, Romania and more | 2 | Active, not recruiting | Klus Pharma | Aug 31, 2026 | 356 |
| NCT05642780Solid Tumor · United States, Australia, Belgium and more | 2 | Active, not recruiting | Klus Pharma | Nov 30, 2027 | 240 |
| NCT05631262Selected Subjects With Advanced Solid Tumors · China | 2 | Active, not recruiting | Sichuan Kelun Pharmaceutical | Dec 30, 2026 | 321 |
| NCT05445908Triple Negative Breast Neoplasms · China | 2 | Completed | Sichuan Kelun Pharmaceutical | Jul 31, 2026 | 184 |
| NCT05351788Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Sichuan Kelun Pharmaceutical | Aug 2026 | 110 |
| NCT05347134Triple Negative Breast Neoplasms · China | 3 | Active, not recruiting | Sichuan Kelun Pharmaceutical | Nov 30, 2023 | 254 |
| NCT05319730Esophageal Squamous Cell Carcinoma · United States, Brazil, Chile and more | 2 | Recruiting | Merck | Jun 11, 2027 | 230 |
| NCT04152499Carcinoma, Ovarian Epithelial · United States, Canada, Chile and more | 2 | Active, not recruiting | Klus Pharma | Nov 30, 2025 | 1,410 |
How it is read
Names in the registry
- “Sacituzumab tirumotecan”, 22 entries
- “SKB264”, 15 entries
- “Sacituzumab Tirumotecan”, 5 entries
- “SKB264+SKB118”, 2 entries
- “sac-TMT”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 14 studies
- Triple Negative Breast Neoplasms, 6 studies
- Breast Neoplasms, 3 studies
- Ovarian Neoplasms, 2 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.